IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11) (H11)
This study has been withdrawn prior to enrollment.
(Study closed due to lack of recruitment)
Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Collaborator:
Polish Lymphoma Research Group
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC
ClinicalTrials.gov Identifier:
NCT01652261
First received: July 18, 2012
Last updated: June 13, 2014
Last verified: June 2014
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The main objective of the trial is to show that doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)-based response-adapted therapy for advanced-stage Hodgkin lymphoma, with treatment intensification (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) in case of a positive fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) after one cycle of ABVD, has non-inferior efficacy compared with the intensive BEACOPPesc regimen. A second objective is to assess the prognostic value of FDG-PET/CT after one cycle of BEACOPPesc.
| Condition | Intervention | Phase |
|---|---|---|
| Hodgkin Lymphoma | Drug: ABVD + FDG-PET/CT Scan treatment adaptation Drug: BEACOPPesc | Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Very Early FDG-PET/CT-response Adapted Therapy for Advanced Stage Hodgkin Lymphoma, a Randomized Phase III Non-inferiority Study of the EORTC Lymphoma Group |
Resource links provided by NLM:
Further study details as provided by European Organisation for Research and Treatment of Cancer - EORTC:
Primary Outcome Measures:
- Freedom from treatment failure [ Time Frame: 9 years after first patient in (FPI) ]
Secondary Outcome Measures:
- response at the end of therapy [ Time Frame: 9 years after FPI ]
- Progression-free survival [ Time Frame: 9 years after FPI ]
- Overall survival [ Time Frame: 9 years after FPI ]
- Acute toxicity [ Time Frame: 9 years after FPI ]
- Hematological toxicity (blood cell count) can be significant especially for patients who will receive BEACOPPesc .
- Bleomycine interstitial pneumonitis has been frequently reported and requires the immediate stop of further bleomycine administration.
- Rarely, procarbazine allergy and intolerance has been reported.
- Nausea & vomiting due to cyclophosphamide, doxorubicin, dacarbazine and procarbazine may be significant.
- Total reversible alopecia occurs in most cases.
- Escalated BEACOPP-related toxic deaths have been reported but do not exceed those observed with standard ABVD.
- Long-term toxicity in terms of second malignancies, cardiovascular and pulmonary events [ Time Frame: 9 years after FPI ]
| Enrollment: | 0 |
| Study Start Date: | May 2013 |
| Estimated Study Completion Date: | March 2022 |
| Estimated Primary Completion Date: | March 2020 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: experimental arm
An experimental arm (early FDG-PET/CT-response adapted), where all patients are initially treated with a single cycle of ABVD. Very early FDG-PET/CT-negative patients continue on ABVD therapy to a total of six cycles. Very early FDG-PET/CT-positive patients receive 3 cycles of BEACOPPesc followed by another 3 cycles of BEACOPPesc. Mid-treatment evaluation is performed after 4 cycles. In case of treatment failure (less than partial remission (PR)), the patient goes off protocol treatment. Only patients with residual FDG-PET/CT-positive disease after chemotherapy will receive radiotherapy (36 Gy/18 fractions on the FDG-PET/CT-positive residual mass(es)). |
Drug: ABVD + FDG-PET/CT Scan treatment adaptation Drug: BEACOPPesc |
|
Active Comparator: standard arm
A standard arm, where patients are treated with four cycles of BEACOPPesc followed by 2 cycles of BEACOPPesc. FDG-PET/CT is performed after one cycle, but with no therapeutic consequences. Mid-treatment evaluation is performed after four cycles. In case of treatment failure (less than PR), the patient goes off protocol treatment. Only patients with residual FDG-PET/CT-positive disease after chemotherapy will receive radiotherapy (36 Gy/18 fractions on the FDG-PET/CT-positive residual mass(es)). |
Drug: BEACOPPesc |
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria:
- Previously untreated, histologically proven classical Hodgkin lymphoma
- Clinical stages III/IV (Ann Arbor)
- Age 18-60
- WHO performance 0-2
- Adequate organ function
- Patients of childbearing/reproductive potential should use adequate birth control measures during the whole duration of study treatment.
- Written informed consent according to ICH/EU Good Clinical Practice, and national/local regulations
Exclusion criteria:
- Pregnancy or lactation
- Specific contraindications to BEACOPPesc therapy, including:
- Poorly controlled diabetes mellitus
- HIV infection,
- Chronic active hepatitis B and/or hepatitis C
- Concomitant or previous malignancies with the exception of basal cell skin tumors, adequately treated carcinoma in situ of the cervix and any cancer that has been in complete remission for >5 years
- Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01652261
Please refer to this study by its ClinicalTrials.gov identifier: NCT01652261
Locations
| Denmark | |
| Rigshospitalet | |
| Copenhagen, Denmark, 2100 | |
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Polish Lymphoma Research Group
Investigators
| Study Chair: | Martin Hutchings | Rigshospitalet, Denmark |
| Study Chair: | Berthe Aleman | The Netherlands Cancer Institute, Amsterdam, The Netherlands |
| Study Chair: | Gustaaf van IMHOFF | University Medical Center Groningen |
| Study Chair: | Wim Oyen | Radboud University |
More Information
| Responsible Party: | European Organisation for Research and Treatment of Cancer - EORTC |
| ClinicalTrials.gov Identifier: | NCT01652261 History of Changes |
| Other Study ID Numbers: |
EORTC-20101-23101 2011-005473-22 ( EudraCT Number ) |
| Study First Received: | July 18, 2012 |
| Last Updated: | June 13, 2014 |
Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
|
advanced stage |
Additional relevant MeSH terms:
|
Lymphoma Hodgkin Disease Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |
ClinicalTrials.gov processed this record on July 21, 2017